Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
7
Expiration
Nov 6, 2026
DTE
17d
Moneyness
ITM
Intrinsic
$1.48
IBRX 7 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $3.00 | +0.00% | 10 | 10 |
| Oct 30, 2026 | 10d | $3.76 | +34.29% | 7 | 7 |
| Nov 6, 2026 | 17d | $3.28 | -9.64% | 1 | 4 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $2.40 | -29.82% | 38 | 1,072 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Mar 19, 2027 | 150d | $4.03 | -4.05% | 1 | 255 |
| Apr 16, 2027 | 178d | $4.48 | +0.00% | 11 | 11 |
| May 21, 2027 | 213d | $4.30 | -4.44% | 5 | 86 |
| Aug 20, 2027 | 304d | $3.90 | -20.41% | 6 | 200 |
| Nov 19, 2027 | 395d | $5.40 | +14.89% | 104 | 121 |
| Mar 17, 2028 | 514d | $5.20 | +4.84% | 20 | 891 |
| Jan 19, 2029 | 822d | $5.80 | -4.92% | 1 | 104 |
IBRX Nearby Strikes · Nov 6, 2026
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.